Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$13.66 +4.2%	$14.98	$10.96 ▼ $32.97	$727.12M	2.22	1.19 million shs	2.03 million shs
FTRE Fortrea	$9.85 +2.1%	$6.27	$3.97 ▼ $25.28	$894.38M	1.81	2.34 million shs	3.57 million shs
PNTG The Pennant Group	$24.01 -1.2%	$25.11	$21.18 ▼ $37.13	$829.83M	1.48	251,662 shs	243,289 shs
XGN Exagen	$9.86 +1.2%	$8.08	$2.38 ▼ $10.34	$216.92M	1.61	231,343 shs	128,870 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	-1.35%	+4.80%	+3.07%	-22.61%	-56.65%
FTRE Fortrea	+6.87%	+24.68%	+51.73%	+123.38%	-57.36%
PNTG The Pennant Group	-0.82%	-1.86%	+5.70%	-16.41%	-28.18%
XGN Exagen	+1.99%	-2.40%	+15.27%	+39.74%	+237.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CDNA CareDx	4.1473 of 5 stars	3.3	2.0	4.2	2.0	0.8	1.9
FTRE Fortrea	3.7202 of 5 stars	4.1	3.0	0.0	2.3	1.7	1.9
PNTG The Pennant Group	4.3274 of 5 stars	3.3	5.0	0.0	2.6	2.5	3.1
XGN Exagen	3.6875 of 5 stars	2.5	1.0	4.5	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDNA CareDx	2.57	Moderate Buy	$27.67	102.54% Upside
FTRE Fortrea	2.17	Hold	$12.22	24.08% Upside
PNTG The Pennant Group	2.60	Moderate Buy	$33.40	39.11% Upside
XGN Exagen	3.00	Buy	$11.25	14.10% Upside

Current Analyst Ratings Breakdown

Latest XGN, PNTG, FTRE, and CDNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2025	CDNA CareDx	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform
8/14/2025	PNTG The Pennant Group	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $29.00
8/8/2025	CDNA CareDx	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$19.00 ➝ $14.00
8/8/2025	FTRE Fortrea	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	In-Line ➝ In-Line	$5.00 ➝ $7.00
8/7/2025	FTRE Fortrea	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underweight ➝ Underweight	$5.00 ➝ $6.00
8/4/2025	FTRE Fortrea	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/4/2025	FTRE Fortrea	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$7.00 ➝ $9.00
7/30/2025	XGN Exagen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$10.00
7/30/2025	XGN Exagen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $11.00
7/30/2025	XGN Exagen	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Weight ➝ Overweight	$12.00
7/23/2025	XGN Exagen	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDNA CareDx	$333.79M	2.18	$1.40 per share	9.77	$6.15 per share	2.22
FTRE Fortrea	$2.70B	0.33	$1.72 per share	5.74	$6.49 per share	1.52
PNTG The Pennant Group	$798.92M	1.04	$0.90 per share	26.56	$9.65 per share	2.49
XGN Exagen	$55.64M	3.90	N/A	N/A	$0.96 per share	10.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDNA CareDx	$52.55M	$1.02	13.39	N/A	N/A	17.97%	18.03%	12.88%	11/3/2025 (Estimated)
FTRE Fortrea	-$328.50M	-$11.38	N/A	7.70	N/A	-37.57%	5.25%	1.72%	11/14/2025 (Estimated)
PNTG The Pennant Group	$22.56M	$0.78	30.78	27.28	2.01	3.36%	9.85%	4.04%	11/5/2025 (Estimated)
XGN Exagen	-$15.11M	-$0.89	N/A	N/A	N/A	-28.85%	-130.38%	-34.69%	11/11/2025 (Estimated)

Latest XGN, PNTG, FTRE, and CDNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	CDNA CareDx	$0.12	-$0.16	-$0.28	-$0.16	$90.72 million	$90.51 million
8/6/2025	Q2 2025	FTRE Fortrea	$0.06	$0.19	+$0.13	-$4.14	$631.61 million	$710.30 million
7/29/2025	Q2 2025	XGN Exagen	-$0.18	-$0.18	N/A	-$0.21	$16.25 million	$17.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
FTRE Fortrea	N/A	N/A	N/A	N/A	N/A
PNTG The Pennant Group	N/A	N/A	N/A	N/A	N/A
XGN Exagen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDNA CareDx	N/A	3.30	3.00
FTRE Fortrea	1.87	1.02	1.02
PNTG The Pennant Group	0.11	1.21	1.21
XGN Exagen	1.06	4.95	4.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDNA CareDx	N/A
FTRE Fortrea	N/A
PNTG The Pennant Group	85.88%
XGN Exagen	75.25%

Insider Ownership

Company	Insider Ownership
CDNA CareDx	4.40%
FTRE Fortrea	0.38%
PNTG The Pennant Group	5.40%
XGN Exagen	12.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDNA CareDx	740	53.23 million	50.89 million	Optionable
FTRE Fortrea	15,500	90.80 million	90.46 million	Optionable
PNTG The Pennant Group	7,000	34.56 million	32.70 million	Optionable
XGN Exagen	220	22.00 million	19.23 million	Optionable

XGN, PNTG, FTRE, and CDNA Headlines

Recent News About These Companies

Stonepine Capital Management LLC Sells 155,302 Shares of Exagen Inc. $XGN

August 26 at 7:38 AM | marketbeat.com

Short Interest in Exagen Inc. (NASDAQ:XGN) Expands By 52.8%

August 20, 2025 | marketbeat.com

Exagen Inc. (NASDAQ:XGN) Given Consensus Recommendation of "Buy" by Brokerages

August 18, 2025 | marketbeat.com

Exagen Inc. to Participate in Third Quarter Investor Conferences

August 6, 2025 | gurufocus.com

Exagen Inc. to Participate in Third Quarter Investor Conferences

August 6, 2025 | globenewswire.com

Exagen Inc. (NASDAQ:XGN) Short Interest Up 144.8% in July

August 4, 2025 | marketbeat.com

BTIG Sticks to Their Buy Rating for Exagen (XGN)

August 2, 2025 | theglobeandmail.com

FY2026 EPS Estimates for Exagen Cut by Cantor Fitzgerald

August 2, 2025 | marketbeat.com

William Blair Has Negative Outlook of Exagen FY2025 Earnings

August 2, 2025 | marketbeat.com

What is KeyCorp's Forecast for Exagen Q3 Earnings?

August 2, 2025 | marketbeat.com

Exagen (XGN) Receives a Buy from Craig-Hallum

August 1, 2025 | theglobeandmail.com

FY2026 Earnings Forecast for Exagen Issued By KeyCorp

August 1, 2025 | marketbeat.com

Exagen Inc. Reports Record Revenue Amidst Growth Challenges

August 1, 2025 | theglobeandmail.com

Canaccord Genuity Sticks to Its Buy Rating for Exagen (XGN)

July 31, 2025 | theglobeandmail.com

Exagen (NASDAQ:XGN) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

July 31, 2025 | marketbeat.com

Exagen (NASDAQ:XGN) Upgraded to "Overweight" at KeyCorp

July 31, 2025 | marketbeat.com

XGN | Exagen Inc. Annual Cash Flow Statement | MarketWatch

July 31, 2025 | marketwatch.com

Keybanc Upgrades Exagen (XGN)

July 31, 2025 | msn.com

Exagen (NASDAQ:XGN) Posts Earnings Results, Hits Estimates

July 30, 2025 | marketbeat.com

Exagen upgraded to Overweight from Sector Weight at KeyBanc

July 30, 2025 | msn.com

Exagen Q2 Revenue Jumps 14 Percent

July 29, 2025 | aol.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN, PNTG, FTRE, and CDNA Company Descriptions

CareDx NASDAQ:CDNA

$13.66 +0.55 (+4.20%)

Closing price 04:00 PM Eastern

Extended Trading

$13.57 -0.09 (-0.66%)

As of 06:22 PM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Fortrea NASDAQ:FTRE

$9.85 +0.20 (+2.07%)

Closing price 04:00 PM Eastern

Extended Trading

$10.12 +0.28 (+2.79%)

As of 06:36 PM Eastern

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

The Pennant Group NASDAQ:PNTG

$24.01 -0.28 (-1.15%)

Closing price 04:00 PM Eastern

Extended Trading

$24.01 0.00 (0.00%)

As of 06:09 PM Eastern

The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors who are independent or who require some support. The company operates home health, hospice, and home care agencies, as well as senior living communities throughout Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.

Exagen NASDAQ:XGN

$9.86 +0.12 (+1.23%)

Closing price 04:00 PM Eastern

Extended Trading

$9.86 0.00 (-0.05%)

As of 04:09 PM Eastern

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time